*Patanjali’s research published in world renowned journal
Excelsior Correspondent
HARIDWAR, July 17: Patanjali Research Centre’s, Acharya Balkrishna has said that in a significant move towards developing herbal medicines for Tuberculosis (TB) treatment, a recent study at Patanjali has highlighted the potential of SolanumVirginianum Extract (SVE) or ‘Chhoti Kateli’ as anti-tubercular therapy.
“This research is part of an initiative aimed at developing herbal therapies that can either stand alone or complement existing anti-TB drugs, with defined mechanisms of action and herb-drug synergism,” Balkrishna informed in a handout.
He stated that the current study tested the biological activity of SVE in Mycobacterium smegmatis, mc2 155, a model system for the investigation of Mycobacterium Tuberculosis (Mtb) showed that bacteria treated with SVE exhibited reduced growth and viability, indicating the extract’s anti-tubercular effects.
“The study further employed a targeted metabolomics approach using UPLC/QToF-MS to detect and quantify intracellular isoniazid (INH) in a complex biological matrix of bacteria which showed that SVE increased the bioavailability of the modern TB drug isoniazid (INH), enhancing the bacteria’s sensitivity to the drug and improving its efficacy,” Balkrishna maintained adding: “In cell line-based infection experiments, the combination of SVE and INH significantly increased bacterial mortality. Additionally, SVE exhibited hepatoprotective effects in human liver cells.”
Acharya Balkrishna further informed that this research of Patanjali has been published in the renowned peer-reviewed journal ‘Frontiers in Microbiology’ and this groundbreaking research lays the foundation for future studies on the anti-mycobacterial properties of Chhoti Kateli extract, offering new hope in the fight against tuberculosis.
Follow our WhatsApp channel
